Browsing Tag
VAX-31
1 post
Pneumococcal vaccine strategy shifts toward scale and integration with Vaxcyte Inc.’s VAX-31 Phase 3 push
Vaxcyte Inc. advances VAX-31 into pivotal trials. Find out what this means for vaccine competition, regulation, and long-term market positioning.